公开(公告)号：US20240343832A1

公开(公告)日：2024-10-17

申请号：US18644757

申请日：2024-04-24

Applicant: AMGEN INC.

Inventor： JOON HOI HUH ,  RIKI STEVENSON ,  PAVEL BONDARENKO ,  ANDREW NICHOLS ,  DA REN ,  NEERAJ JAGDISH AGRAWAL ,  RICHARD SMITH

IPC: C07K16/40 ,  C07K16/28 ,  G01N11/14

CPC classification number: C07K16/40 ,  C07K16/2869 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  G01N11/14

Abstract: The present invention concerns a method for preparing antigen binding proteins specific for PCSK9 with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.

公开(公告)号：US20240309103A1

公开(公告)日：2024-09-19

申请号：US18680910

申请日：2024-05-31

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Michael E. DUNN ,  Jia SU ,  Jason MASTAITIS ,  Jesper GROMADA ,  Lori C. MORTON

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  A61P3/04 ,  A61P9/02 ,  A61P9/12

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61P3/04 ,  A61P9/02 ,  A61P9/12 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to NPR1. In some embodiments, the antibodies of the invention are useful for activating NPR1 activity, thus providing a means of treating or preventing a disease, disorder or condition associated with NPR1 in humans.

公开(公告)号：US20240199754A1

公开(公告)日：2024-06-20

申请号：US18286895

申请日：2022-05-17

Applicant: VANCOUVER BIOTECH LTD.

Inventor： Chi-Yu Gregory Lee

IPC: C07K16/28 ,  A61K39/00 ,  A61P5/24

CPC classification number: C07K16/2869 ,  A61P5/24 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76

Abstract: GHR-106 monoclonal antibody or antigen-binding fragments thereof are provided and used to modulate levels of reproductive hormones in vivo when administered to mammalian subjects. The GHR-106 monoclonal antibody or an antigen-binding fragment thereof can be used to control ovulation, terminate ectopic pregnancy, and/or treat reproductive disorders or conditions in mammalian subjects.

公开(公告)号：US20240150448A1

公开(公告)日：2024-05-09

申请号：US18545688

申请日：2023-12-19

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish AGRAWAL ,  Irwin CHEN ,  Su CHONG ,  Bryna FUCHSLOCHER ,  Kevin GRAHAM ,  Agnes Eva HAMBURGER ,  Mark Leo MICHAELS ,  Christopher MOHR ,  Derek E. PIPER ,  Kenneth William WALKER ,  Zhulun WANG ,  Cen XU

IPC: C07K16/18 ,  A61K38/22 ,  A61P25/06 ,  C07K16/28

CPC classification number: C07K16/18 ,  A61K38/2278 ,  A61P25/06 ,  C07K16/2869 ,  A61K2039/545 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US20240084023A1

公开(公告)日：2024-03-14

申请号：US18342572

申请日：2023-06-27

Applicant: NGM Biopharmaceuticals, Inc.

Inventor： Wenyan Shen ,  Yan Wang ,  Hugo Matern ,  Zhonghao Liu

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2869 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/565

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.

公开(公告)号：US11891435B2

公开(公告)日：2024-02-06

申请号：US17558032

申请日：2021-12-21

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish Agrawal ,  Kevin Graham ,  Agnes Eva Hamburger ,  Christopher Mohr ,  Derek E. Piper ,  Kenneth William Walker ,  Zhulun Wang ,  Cen Xu

IPC: C07K16/00 ,  A61K39/395 ,  A61K39/00 ,  A61K49/00 ,  A61K49/16 ,  C12P21/08 ,  G01N33/53 ,  C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22 ,  A61K47/68 ,  A61K38/17 ,  A61K51/10 ,  C07K14/575 ,  C07K16/26 ,  C07K14/72 ,  C07K14/47 ,  G01N33/74 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K38/2278 ,  A61P25/06 ,  C07K16/2869 ,  A61K38/1796 ,  A61K38/22 ,  A61K47/6843 ,  A61K47/6849 ,  A61K51/10 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2300/00 ,  C07K14/47 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/72 ,  C07K16/00 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C12N2501/30 ,  G01N33/6854 ,  G01N33/6896 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/5757 ,  Y02A50/30

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US20230346932A1

公开(公告)日：2023-11-02

申请号：US18155644

申请日：2023-01-17

Applicant: Gmax Biopharm LLC.

Inventor： Cheng Zhang ,  Kesuo Fan ,  Yong Guo ,  Chenjiang Yao ,  Hua Zhang ,  Xiaofeng Wang ,  Shuqian Jing

IPC: A61K39/395 ,  A61P35/00 ,  A61P11/00 ,  A61P9/12 ,  C07K16/28 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26

CPC classification number: A61K39/39591 ,  A61P35/00 ,  A61P11/00 ,  A61P9/12 ,  A61K39/395 ,  C07K16/28 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  C07K16/2869 ,  A61K2039/505

Abstract: Provided herein are a stable solution formulation of an ETAR antibody, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension or one or more symptoms of cancer of a reproductive organ.

公开(公告)号：US20230331859A1

公开(公告)日：2023-10-19

申请号：US18310796

申请日：2023-05-02

Applicant: 9 Meters Biopharma, Inc.

Inventor： Patrick H. GRIFFIN ,  Nir BARAK ,  Sireesh APPAJOSYULA

IPC: C07K16/28 ,  A61P1/00 ,  A61K9/00

CPC classification number: C07K16/2869 ,  A61P1/00 ,  A61K9/0019 ,  A61K38/00

Abstract: The present invention provides methods for treating short bowel syndrome and/or high output ostomy. The invention comprises administering to a patient in need a long-acting GLP-1 receptor agonist. In various embodiments, the method reduces ostomy output, reduces requirement for parenteral nutrition, and/or ameliorates acute intestinal failure.

公开(公告)号：US11773150B2

公开(公告)日：2023-10-03

申请号：US17004395

申请日：2020-08-27

Applicant: Merck Sharp & Dohme LLC ,  Ambrx, Inc.

Inventor： Paul E. Carrington ,  Grigori Ermakov ,  Robert M. Garbaccio ,  Wolfgang Seghezzi ,  Elisabetta Bianchi ,  Federica Orvieto ,  Dennis Gately ,  Nick Knudsen ,  Anthony Manibusan

IPC: C07K14/605 ,  C07K16/26 ,  C07K16/28 ,  A61K47/68 ,  A61P3/10 ,  A61K39/00

CPC classification number: C07K14/605 ,  A61K47/6811 ,  A61K47/6843 ,  A61P3/10 ,  C07K16/26 ,  C07K16/2869 ,  A61K2039/505 ,  C07K2317/75 ,  C07K2319/00

Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

公开(公告)号：US20230295271A1

公开(公告)日：2023-09-21

申请号：US17928690

申请日：2021-06-02

Applicant: University of Southern California

Inventor： Myron F. Goodman ,  Michael Lieber ,  Phuong Pham

IPC: C07K16/00 ,  C12N15/10 ,  C07K16/28 ,  C07K16/40

CPC classification number: C07K16/005 ,  C12N15/1093 ,  C07K16/2869 ,  C07K16/40 ,  C07K2317/622

Abstract: Methods and systems are provided to induce hypermutation, produce phage libraries displaying mutagenized immunoglobulin variable regions, and conduct affinity maturation based on the use of activation-induced deoxycytidine deaminase (AID) and a low fidelity DNA polymerase eta (pol η). High affinity monoclonal antibodies or antigen-binding fragments thereof produced by these methods are also demonstrated.